Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BACH MEDICAL GROUP, INC.

NPI: 1902280019 · IRVINE, CA 92614 · Dermatopathology (Pathology) Physician · NPI assigned 07/17/2015

$6.13M
Total Medicaid Paid
158,273
Total Claims
78,712
Beneficiaries
26
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialBACH, DYLAN (MEDICAL DIRECTOR)
NPI Enumeration Date07/17/2015

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 7,098 $142K
2019 1,018 $16K
2020 12,017 $658K
2021 38,677 $1.57M
2022 58,989 $2.16M
2023 33,856 $1.38M
2024 6,618 $201K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 56,247 20,528 $3.54M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 48,380 18,549 $810K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 5,539 5,370 $603K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 3,707 2,340 $377K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 5,466 1,982 $203K
88305 Level IV - Surgical pathology, gross and microscopic examination 3,090 3,045 $165K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 14,853 6,556 $98K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,140 1,112 $77K
87150 537 511 $35K
88312 4,075 4,025 $34K
87481 2,195 2,114 $29K
86769 843 747 $23K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 168 168 $18K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 883 862 $17K
88304 1,459 1,444 $15K
87500 665 636 $13K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 1,025 950 $12K
87653 1,026 952 $12K
87641 567 537 $11K
88311 4,458 4,410 $10K
87640 834 771 $9K
0109U 173 172 $6K
88313 397 397 $6K
88302 237 236 $3K
36415 Collection of venous blood by venipuncture 297 286 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 12 12 $0.00